{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:07Z","timestamp":1772164807167,"version":"3.50.1"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"crossref","award":["19-035-ASP"],"award-info":[{"award-number":["19-035-ASP"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tumor mutational burden (TMB) has been investigated as a biomarker for immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene panel\u2013based assays (as opposed to full exome sequencing) and different gene panels cover overlapping but distinct genomic coordinates, making comparisons across panels difficult. Previous studies have suggested that standardization and calibration to exome-derived TMB be done for each panel to ensure comparability. With TMB cutoffs being developed from panel-based assays, there is a need to understand how to properly estimate exomic TMB values from different panel-based assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Our approach to calibration of panel-derived TMB to exomic TMB proposes the use of probabilistic mixture models that allow for nonlinear relationships along with heteroscedastic error. We examined various inputs including nonsynonymous, synonymous, and hotspot counts along with genetic ancestry. Using The Cancer Genome Atlas cohort, we generated a tumor-only version of the panel-restricted data by reintroducing private germline variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We were able to model more accurately the distribution of both tumor-normal and tumor-only data using the proposed probabilistic mixture models as compared with linear regression. Applying a model trained on tumor-normal data to tumor-only input results in biased TMB predictions. Including synonymous mutations resulted in better regression metrics across both data types, but ultimately a model able to dynamically weight the various input mutation types exhibited optimal performance. Including genetic ancestry improved model performance only in the context of tumor-only data, wherein private germline variants are observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A probabilistic mixture model better models the nonlinearity and heteroscedasticity of the data as compared with linear regression. Tumor-only panel data are needed to properly calibrate tumor-only panels to exomic TMB. Leveraging the uncertainty of point estimates from these models better informs cohort stratification in terms of TMB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0339","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:11:37Z","timestamp":1677233497000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-4113","authenticated-orcid":true,"given":"Jordan","family":"Anaya","sequence":"first","affiliation":[{"name":"1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5575-0285","authenticated-orcid":true,"given":"John-William","family":"Sidhom","sequence":"additional","affiliation":[{"name":"2The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"3Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"4Bloomberg\u223cKimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-9474","authenticated-orcid":true,"given":"Craig A.","family":"Cummings","sequence":"additional","affiliation":[{"name":"5Department of Oncology Biomarker Development, Genentech, South San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-3342","authenticated-orcid":true,"given":"Alexander S.","family":"Baras","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"4Bloomberg\u223cKimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for AACR Project GENIE Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-016-9652-y","article-title":"Next generation predictive biomarkers for immune checkpoint inhibition","volume":"36","author":"Khagi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Allen","year":"2015","journal-title":"Science"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"703","DOI":"10.21037\/tlcr.2018.08.14","article-title":"Implementing tumor mutational burden (TMB) analysis in routine diagnostics\u2014a primer for molecular pathologists and clinicians","volume":"7","author":"Allg\u00e4uer","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"e000442","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB measurement in clinical practice: considerations on assay requirements","volume":"4","author":"B\u00fcttner","year":"2019","journal-title":"ESMO Open"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels","volume":"144","author":"Endris","year":"2019","journal-title":"Int J Cancer"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023032814062124700_","article-title":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors 2020","author":"FDA"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.annonc.2020.07.001","article-title":"The FDA approval of pembrolizumab for patients with TMB &gt;10 mut\/Mb: was it a wise decision? No","volume":"31","author":"Prasad","year":"2020","journal-title":"Ann Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"viii45","DOI":"10.1093\/annonc\/mdy269.139","article-title":"Tumor mutational burden (TMB) standardization initiative: Establishing a consistent methodology for TMB measurement in clinical samples","volume":"29","author":"Stenzinger","year":"2018","journal-title":"Ann Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.31878","article-title":"Size matters: dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"Buchhalter","year":"2019","journal-title":"Int J Cancer"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"Budczies","year":"2019","journal-title":"Ann Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"2023032814062124700_","article-title":"Adding uncertainty to neural network regression tasks in the geosciences","author":"Barnes","year":"2021"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1038\/s41467-020-18151-y","article-title":"Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples","volume":"11","author":"Bailey","year":"2020","journal-title":"Nat Commun"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","article-title":"Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating discovery of functional mutant alleles in cancer","volume":"8","author":"Chang","year":"2018","journal-title":"Cancer Discov"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2018.08.019","article-title":"Integrated analysis of genetic ancestry and genomic alterations across cancers","volume":"34","author":"Yuan","year":"2018","journal-title":"Cancer Cell"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/bioinformatics\/btz615","article-title":"PyRanges: efficient comparison of genomic intervals in Python","volume":"36","author":"Stovner","year":"2020","journal-title":"Bioinformatics"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"Gigascience"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/humu.24309","article-title":"Variant interpretation using population databases: lessons from gnomAD","volume":"43","author":"Gudmundsson","year":"2022","journal-title":"Hum Mutat"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"640","DOI":"10.21037\/atm.2019.10.116","article-title":"Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers","volume":"7","author":"Wu","year":"2019","journal-title":"Ann Transl Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13073-016-0333-9","article-title":"The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine","volume":"8","author":"Garofalo","year":"2016","journal-title":"Genome Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40291-019-00408-y","article-title":"Bioinformatic methods and bridging of assay results for reliable tumor mutational burden assessment in non-small-cell lung cancer","volume":"23","author":"Chang","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmoldx.2018.09.008","article-title":"Somatic tumor variant filtration strategies to optimize tumor-only molecular profiling using targeted next-generation sequencing panels","volume":"21","author":"Sukhai","year":"2019","journal-title":"J Mol Diagn"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"e200202","DOI":"10.1001\/jamanetworkopen.2020.0202","article-title":"Tumor mutational burden from tumor-only sequencing compared with germline subtraction from paired tumor and normal specimens","volume":"3","author":"Parikh","year":"2020","journal-title":"JAMA Network Open"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","article-title":"Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study","volume":"15","author":"Stenzinger","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-021-00164-5","article-title":"Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups","volume":"5","author":"Asmann","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of cancer research TMB harmonization project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Nat Cancer"},{"key":"2023032814062124700_","doi-asserted-by":"crossref","DOI":"10.1101\/2022.02.16.480761","article-title":"Read depth correction for somatic mutations","volume-title":"Biorxiv","author":"Anaya","year":"2022"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0339\/3276673\/crc-22-0339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/3\/501\/3287107\/crc-22-0339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/3\/501\/3287107\/crc-22-0339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:04:27Z","timestamp":1701954267000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/3\/501\/719022\/Probabilistic-Mixture-Models-Improve-Calibration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,28]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0339","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6489305.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2022.04.22.489230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6489305","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.22348739.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348562.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348727.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348733","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348733.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348562","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348724.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348736.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22348730.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}